Gynecology

 

 
Workshop in Urogynecology
Sessions 1-2
 08:30-10:50
UROGYNECOLOGY WORKSHOP
 Capsule
Urinary incontinence and utero-vaginal prolapse affect more than 50% of women. The management of these two common problems has evolved over time, with surgeries getting more and more minimally invasive to non-invasive. It is time to have an update on the management of these common problems
 Session 1
UROGYNECOLOGY I
 Capsule

The incidence of occult Stress Urinary Incontinence (SUI) in patients with severe utero-vaginal prolapse is up 30%. Much discussion has been centered on whether incontinence surgery should be performed at the time of prolapse surgery. There are many surgical techniques for severe utero-vaginal prolapse. Reduction of the incidence of recurrence of prolapse has long been a difficult challenge. Colpocleisis may offer a low recurrence rate, but will it put an end to sexual intercourse.  Is colpocleisis still a feasible way to manage severe prolapse?
 Chairperson

Christopher Chong, Singapore
 08:30-09:00

Update in the management of stress urinary incontinence
Christopher Chong, Singapore
 09:00-10:00
Debate: We do not need to do incontinence surgery for occult SUI.  Colpocleisis is the surgery of choice for patients who are not sexually active
For: Zhu Lan, China  
Against: Jennifer Marie B. Jose, Philippines  
Discussion
 10:00-10:20 Coffee Break
 10:20-11:50
UROGYNECOLOGY II
Supported in part by Fotona
 Capsule

With the advancement of medical science, there is a move towards less invasive and even non-invasive surgeries. In recent years, laser has been used to treat SUI and utero-vaginal prolapse in an attempt to offer non-invasive surgery. Laser has also been marketed for vaginal rejuvenation and vaginal cosmetic surgery. Is this the way to go?
 Chairpersons

Zhu Lan, China
Christopher Chong, Singapore

 10:20-10:50

Update in the management of pelvic organ prolapse
Christopher Chong, Singapore

 10:50-11:50
Debate:  Laser therapy is an effective way to manage SUI and utero-vaginal prolapse
For: Adolf Lukanovic, Slovenia
Against: Jennifer Marie B. Jose, Philippines
Discussion

 11:50-12:40

 Lunch break

 

 12:40-14:10
OC’s AND THROMBOEMBOLISM
 Capsule
Thromboembolism is a threatening complication of OC’s. What is the difference between various preparations in the market?
 Chairpersons
Alfred O. Mueck, Germany
Gary Ventolini, USA
 12:40-13:10 Mechanism of OC’s related thrombosis
Sven Skouby, Denmark
 13:10-13:40
Is the risk of thromboembolism different with different pills?
Alfred O. Mueck, Germany
 13:40-14:10 Vaginal Lactobacilli and biofilm formation
Gary Ventolini, USA
 14:10-14:30 Poster viewing

   

 14:30-16:00
 CONTROVERSIES IN HPV AND CANCER PREVENTION
Supported in part by Hybribio
Supported in part by Qiagen
 Capsule Explaining HPV vaccines and screening to tens of thousands of health professionals in China requires the combined achievements of face-to-face conferences and e-learning technologies.  This course attempts to do so for the fast evolving HPV field. 
 Chairpersons

You-Lin Qiao, China
Chang Ping Zou, China
 14:30-14:40 Epidemiology of HPV and cancer. Burden of disease and potential for prevention in screening and vaccination
Xavier Bosch, Spain
 14:40-14:50 The process of the cervical cancer screening in China
Zeyi Cao, China
 14:50-15:00 HPV tests for screening in China.  Studies and choices
You-Lin Qiao, China
  15:00-15:10 The value and opportunities of HPV vaccines
Hextan YS Ngan, Hong Kong
 15:10-15:20 Vaccine trials in China: Acceptability and safety considerations
Chang Ping Zou, China
 15:20-16:00

Moderator: Xavier Bosch, Spain 

Selected questions and discussions with the audience: 

1.Future plans for cervical cancer prevention in China: Screening 
    -The HPV tests that are suitable for very large populations and rural areas
    -Self-sampling for HPV tests 
2. HPV vaccination in China 
    -How to vaccinate very large populations
    -How to monitor vaccination impact
3. Updating indications for HPV vaccination 
    -Male vaccination
    -Extending the target age groups to age 30+
    -As part of the treatment of CIN2+
4. The safety crisis in HPV vaccination in japan 
    -Safety assessment of HPV vaccines
    -The international network of vaccine safety surveillance 
5.Other questions from the panel or the audience

 
 16:00-16:30

 Coffee break

   

 16:30-18:00
 SURGICAL AND MEDICAL TREATMENT OF FIBROIDS
 Chairpersons
Mark Brincat, Malta
Talia Levy, Israel
 16:30-17:00
 Endoscopic myomectomy in infertility: Limitations and complications
Jacques Donnez, Belgium
 17:00-17:30

SPRMs mechanism of action on fibroids
Philippe Bouchard, France
 17:30-18:00 Morcellation of fibroids and risk of adverse effect
Salim Daya, Canada

   

 08:30-10:00
 HORMONAL THERAPY IN MENOPAUSE
 Capsule
Many studies claim that we overreacted to the WHI results. Why has HRT never bounced back?
 Chairpersons Sven Skouby, Denmark
Xiangyan Ruan, China
 08:30-09:00
The WHI: Where the right went wrong
Robert Langer, USA
 09:00-09:30
Estrogens: Are they really carcinogenic?
Alfred O. Mueck, Germany
 09:30-10:00
Is HRT still the main answer for menopause?
Sven Skouby, Denmark
 10:00-10:20  Coffee break

 

 10:20-11:50
 NEWER OPTIONS FOR HT
 
Supported in part by Fotona
Capsule
The slow bouncing of hormonal prescriptions requires a new solution
Chairpersons Alfred O. Mueck, Germany
Xiangyan Ruan, China
 10:20-10:40
Efficacy and safety of conjugated estrogens/bazedoxifene (CE/BZA)
Mark Brincat, Malta
 10:40-11:05
The WHI and osteoporosis
Robert Langer, USA
 11:05-11:25
Non-hormonal treatment of menopause
Sven Skouby, Denmark
 11:25-11:50
Laser for vulvovaginal atrophy: Is it real?
Adrian Gaspar, Argentina
 11:50-12:40
 Lunch break
 12:40-13:40
NATURAL PROGESTERONE PREFERRED CHOICE FOR MENSTRUATION REGULATION, REPRODUCTION AND MENOPAUSE
Supported by Zhejiang Xianju Pharmaceutical Co. Ltd
 Chairperson Jie Qiao, China
 12:40-12:45 Introduction
Jie Qiao, China
 12:45-13:35 Progesterone: Preferred choice for menstruation regulation, reproduction and menopause
Xiangyan Ruan, China
 13:30-13:35 Summary 
Jie Qiao, China
 13:35-13:40 Q&A
Xiangyan Ruan, China
13:40-14:10 Free Communication
14:10-14:30 Poster Viewing 

   

 

 14:30-15:30
GYNECOLOGICAL CANCER
 Chairpersons
Talia Levy, Israel
Pengpeng Qu, China
 14:30-14:50 Hot topic of ovarian cancer screening
Pengpeng Qu, China
 14:50-15:10
Talia Levy, Israel
 15:10-15:30
Disputed treatment strategies of Vaginal Intraepithelial Neoplasia (VaIN): Advantages and disadvantages
Long Sui, China
 15:30-16:00
Chinese e-learning course on cervical cancer prevention:
THE WAY FORWARD IN MEDICAL EDUCATION
 Capsule                

Explaining HPV vaccines and screening to tens of thousands of health
professionals in China requires the combined achievements of the face-to-face conferences and the e-learning technologies. This course attempts to do so in the fast evolving HPV field
 Chairpersons

You-Lin Qiao, China
Xavier Bosch, Spain
Zion Ben-Rafael, Israel
 16:00-16:30

Coffee break

   

 16:30-18:00
RISK OF BREAST CANCER AND HRT
 Capsule
Fear of breast cancer is the main reason for the massive drop in HT. Is it justified?
 Chairpersons
Robert Langer, USA
Sven Skouby, Denmark
 16:30-16:50
The WHI and breast cancer
Robert Langer, USA 
 16:50-17:35
Debate: Breast cancer and HRT: Risk or protection?
Pro risk: Xiangyan Ruan, China 
Pro protection: Alfred O. Mueck, Germany 
Discussion
 17:35-18:00
Pharmacological interventions in the prevention of breast cancer
Mark Brincat, Malta